TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+14.35%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.65B
AUM Growth
+$2.65B
(+8.4%)
Cap. Flow
-$85M
Cap. Flow
% of AUM
-3.21%
Top 10 Holdings %
Top 10 Hldgs %
39.13%
Holding
181
New
13
Increased
25
Reduced
35
Closed
9
Top Buys
| 1 |
Eli Lilly
LLY
|
$17.7M |
| 2 |
Pfizer
PFE
|
$16.7M |
| 3 |
Biogen
BIIB
|
$13.8M |
| 4 |
McKesson
MCK
|
$12.3M |
| 5 |
Avantor
AVTR
|
$9.69M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$36.3M |
| 2 |
Johnson & Johnson
JNJ
|
$25.5M |
| 3 |
Humana
HUM
|
$18.1M |
| 4 |
AstraZeneca
AZN
|
$17M |
| 5 |
Molina Healthcare
MOH
|
$15.2M |
Sector Composition
| 1 | Healthcare | 97.55% |
| 2 | Real Estate | 1.68% |
| 3 | Industrials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
argenx
ARGX
$43.6B
| $31.8M | 1.2% | 84,021 +7,386 | +10% | +$2.8M |
|
27
Intuitive Surgical
ISRG
$170B
| $29.9M | 1.13% | 112,680 +8,277 | +8% | +$2.2M |
|
28
Jazz Pharmaceuticals
JAZZ
$7.75B
| $29.1M | 1.1% | 182,782 | – | – |
|
29
Danaher
DHR
$147B
| $28.1M | 1.06% | 105,690 -18,866 | -15% | -$5.01M |
|
30
Idexx Laboratories
IDXX
$51.8B
| $27.8M | 1.05% | 68,065 +13,858 | +26% | +$5.65M |
|
31
Medtronic
MDT
$119B
| $25.4M | 0.96% | 326,172 | – | – |
|
32
HCA Healthcare
HCA
$94.5B
| $25.2M | 0.95% | 105,003 -19,300 | -16% | -$4.63M |
|
|
33
McKesson
MCK
$85.4B
| $24.9M | 0.94% | 66,455 +32,798 | +97% | +$12.3M |
|
34
DexCom
DXCM
$29.5B
| $24.7M | 0.93% | 218,015 -27,697 | -11% | -$3.14M |
|
|
35
Molina Healthcare
MOH
$9.8B
| $24.3M | 0.92% | 73,615 -45,920 | -38% | -$15.2M |
|
36
BioMarin Pharmaceuticals
BMRN
$11.2B
| $23.9M | 0.9% | 230,790 +79,843 | +53% | +$8.26M |
|
37
Zoetis
ZTS
$69.3B
| $20.1M | 0.76% | 136,914 | – | – |
|
38
Sarepta Therapeutics
SRPT
$1.78B
| $18.3M | 0.69% | 140,959 -25,000 | -15% | -$3.24M |
|
39
Novo Nordisk
NVO
$251B
| $17.7M | 0.67% | 130,523 | – | – |
|
40
Lantheus
LNTH
$3.73B
| $17.5M | 0.66% | 342,872 +113,693 | +50% | +$5.79M |
|
41
Charles River Laboratories
CRL
$8.04B
| $15.8M | 0.6% | 72,675 | – | – |
|
42
BioNTech
BNTX
$24B
| $15.6M | 0.59% | 103,858 +8,816 | +9% | +$1.32M |
|
43
Ascendis Pharma
ASND
$11.8B
| $15.1M | 0.57% | 123,791 +55,997 | +83% | +$6.84M |
|
44
uniQure
QURE
$896M
| $14.8M | 0.56% | 652,446 +130,753 | +25% | +$2.96M |
|
|
SGEN
45
DELISTED
Seagen Inc. Common Stock
SGEN
| $14.4M | 0.54% | 112,214 +58,827 | +110% | +$7.56M |
|
46
Neurocrine Biosciences
NBIX
$13.8B
| $13.5M | 0.51% | 112,908 -55,200 | -33% | -$6.59M |
|
47
IQVIA
IQV
$32.4B
| $12.9M | 0.49% | 63,117 -4,700 | -7% | -$963K |
|
48
Guardant Health
GH
$8.41B
| $12.8M | 0.49% | 472,184 +126,100 | +36% | +$3.43M |
|
49
Edwards Lifesciences
EW
$47.8B
| $12.8M | 0.48% | 171,388 | – | – |
|
50
ResMed
RMD
$40.2B
| $12.6M | 0.48% | 60,699 | – | – |
|